HUTCHMED Completes Rolling Submission of NDA to FDA for Fruquintinib HUTCHMED (China) Limited announced the completion of the rolling submission of a New Drug Application ("NDA") to the United States Food and Drug Administration ("FDA") for fruquintinib, its highly selective and potent oral inhibitor of VEGFR-1,...
Find MoreColorectal Cancer is a formidable health problem worldwide which is the third most common cancer diagnosed among men and women. It arises as a polyp which later develops into a life-threatening cancer; it occurs due to the unrestrained cell growth in appendix, colon, and the rectum region. High incidence rate is obs...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.